Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New study offers hope for ASF vaccine
ASF currently has no vaccine but the disease is spreading further across Europe. (stock photo)
Deleting a gene reduces ability to cause infection 

Genetically altering the African swine fever virus could offer the key to a much-needed vaccine for the deadly disease, Pirbright scientists say.

Researchers found that by deleting a gene of the virus, it was still able to replicate, but its ability to cause infection was dramatically reduced. The gene they deleted codes for a protein thought to play a role in suppressing the pig immune system.

All pigs involved in the study survived, and displayed only mild clinical signs. Furthermore, they were protected against further infection from a natural strain of ASFV, which causes severe disease.

ASF currently has no vaccine but the disease is spreading further across Europe, with outbreaks recently reported in Romania for the first time. Current prevention strategies are focused on import controls and educating farm owners, but the Pirbright Institute says these tools are not robust enough to stop the spread of disease across Eastern Europe and Russia.

The research team believe that further research could lead to an ASF vaccine. Their research shows the modified virus could be used as a component of a live attenuated vaccine, which contains a weakened version of the virus that is able to cause an immune response, without causing the animal harm.

However, issues with safety and effectiveness must be resolved before it is available commercially. The next step will be to make more gene deletions to reduce the clinical signs displayed by pigs after vaccination.

Dr Nixon added: “We will also be investigating the precise role the protein plays during infection. This information will help us understand how it interacts with the host immune system and if the protein directly prevents immune processes or if it has other roles we haven’t yet identified.

“Knowing more about the gene and protein will make it easier for us to modify the virus further and create a vaccine that is effective and safe.”

The findings have been published in the Journal of Virology.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.